Overview Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Adult Chinese Patients With TIO Status: Not yet recruiting Trial end date: 2023-12-01 Target enrollment: Participant gender: Summary The purpose of this study is to assess the safety, pharmacokinetics and efficacy of KRN23 in adult Chinese patients with TIO Phase: Phase 4 Details Lead Sponsor: Kyowa Kirin Co., Ltd.